Overview

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Status:
Recruiting

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)

Phase:

Phase 2

Details

Lead Sponsor:

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Treatments:

Cyclophosphamide